Literature DB >> 10411470

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

M Zewail-Foote1, L H Hurley.   

Abstract

The ecteinascidins (Ets), which are natural products derived from marine tunicates, exhibit potent antitumor activity. Of the numerous Ets isolated, Et 743 is presently being evaluated in phase II clinical trials. Et 743 binds in the minor groove of DNA and alkylates N2 of guanine. Although structurally similar to saframycin, which exhibits poor activity in cellular assays, Et 743 has shown good efficacy as an antitumor agent. In this study, DNA structural distortions induced by Et 743 were examined to provide insight into the molecular basis for the antitumor activity of Et 743. Electrophoretic mobility shifts of ligated oligomers containing site-directed adducts were used to examine the extent and direction of the Et 743-induced bend. Surprisingly, we find that Et 743 bends DNA toward the major groove, which is a unique feature among DNA-interactive agents that occupy the minor groove.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411470     DOI: 10.1021/jm990241l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  58 in total

1.  Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.

Authors:  Laura Vidal; Margarita Magem; Clare Barlow; Beatriz Pardo; Amalia Florez; Ana Montes; Margarita Garcia; Ian Judson; Claudia Lebedinsky; Stan B Kaye; Ramón Salazar
Journal:  Invest New Drugs       Date:  2010-10-07       Impact factor: 3.850

2.  Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.

Authors:  Lia Gore; E Rivera; M Basche; S L Moulder-Thompson; J Li; S Eppers; S Grolnic; C O'Bryant; D Cleere; Y A Elsayed; S G Eckhardt
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

3.  Diepoxybutane interstrand cross-links induce DNA bending.

Authors:  Julie T Millard; Erin E McGowan; Sharonda Q Bradley
Journal:  Biochimie       Date:  2011-08-04       Impact factor: 4.079

4.  Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

Authors:  M Tavecchio; C Natoli; P Ubezio; E Erba; M D'Incalci
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

Review 5.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

6.  Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.

Authors:  Cristiana Sessa; Gianluca Del Conte; Alexandre Christinat; Sara Cresta; Antonella Perotti; Elisa Gallerani; Pilar Lardelli; Carmen Kahatt; Vicente Alfaro; Jorge L Iglesias; Carlos Fernández-Teruel; Luca Gianni
Journal:  Invest New Drugs       Date:  2013-03-07       Impact factor: 3.850

Review 7.  Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.

Authors:  V H Le; M Inai; R M Williams; T Kan
Journal:  Nat Prod Rep       Date:  2015-02       Impact factor: 13.423

8.  A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.

Authors:  Axel Le Cesne; Alejandro Yovine; Jean-Yves Blay; Suzette Delaloge; Robert G Maki; Jean-Louis Misset; Pilar Frontelo; Antonio Nieto; Juhui James Jiao; George D Demetri
Journal:  Invest New Drugs       Date:  2011-04-12       Impact factor: 3.850

9.  Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.

Authors:  Gianmaria Miolo; Alessandra Viel; Vincenzo Canzonieri; Tania Baresic; Angela Buonadonna; Davide Adriano Santeufemia; Della Puppa Lara; Giuseppe Corona
Journal:  Cancer Biol Ther       Date:  2016-10-02       Impact factor: 4.742

10.  Role of trabectedin in the treatment of soft tissue sarcoma.

Authors:  Alexandre Christinat; Serge Leyvraz
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.